OncoSec Medical Inc.
Electroporation drug delivery for advanced skin cancer
This article was originally published in Start Up
OncoSec Medical Inc. has developed electroporation-based technology for deadly Stage III and IV metastatic melanoma, and two rare but aggressive orphan skin cancer indications. Its ImmunoPulse platform delivers DNA IL-12 into electroporated cells, triggering each cell to produce and secrete the IL-12 protein, which in turn identifies and eliminates cancerous cells as part of a natural immune response.
You may also be interested in...
Nanotechnology, electroporation, and superficial radiotherapy are some of the tools device start-ups are deploying as alternatives to toxic drug regimens and surgery for treating skin cancer. We profile three emerging companies in this issue: OncoSec Medical, Sensus Healthcare, and Siva Therapeutics.
Sandoz announced more than a year ago that its GP2411 biosimilar denosumab candidate had entered the clinic. Management provided an update on its progress at the recent Virtual Meet Novartis Management Investor Event.
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from fellow Indian firm Glenmark.